Purine inhibitors of human phosphatidylinositol 3-kinase delta

US11230547B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Meredeth A. McGowan · Boston, US
• Jason Katz · Leominster, US
• Matthew Christopher · Brookline, US
• Hua Zhou · Acton, US
• David J. Witter · Norfolk, US
• Chaomin Li · Boston, US
• John W. Lampe · Orange, US
• Joey L. Methot · Westwood, US
• Abdelghani Achab · Melrose, US
• Xavier Fradera · Brookline, US
• Shimin Xu · Beijing, CN

Key dates

• Filing date: Dec 12, 2018
• Grant date: Jan 25, 2022
• Expiry date: Dec 12, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The instant invention provides compounds of formulas Ia and Ib which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.